Metabolic syndrome in children with chronic kidney disease and after renal transplantation
- First Online:
- Cite this article as:
- Litwin, M. & Niemirska, A. Pediatr Nephrol (2014) 29: 203. doi:10.1007/s00467-013-2500-1
- 1.4k Views
Visceral obesity and metabolic abnormalities typical for metabolic syndrome (MS) are the new epidemic in adolescence. MS is not only the risk factor for cardiovascular disease but also for chronic kidney disease (CKD). Thus, there are some reasons to recognize MS as a new challenge for pediatric nephrologists. First, hypertensive and diabetic nephropathy, the main causes of CKD in adults, both share the same pathophysiological abnormalities associated with visceral obesity and insulin resistance and have their origins in childhood. Secondly, as the obesity epidemic also affects children with CKD, MS emerges as the risk factor for progression of CKD. Thirdly, metabolic abnormalities typical for MS may pose additional risk for cardiovascular morbidity and mortality in children with CKD. Finally, although the renal transplantation reverses uremic abnormalities it is associated with an exposure to new metabolic risk factors typical for MS and MS has been found to be the risk factor for graft loss and cardiovascular morbidity after renal transplantation. MS is the result of imbalance between dietary energy intake and expenditure inducing disproportionate fat accumulation. Thus, the best prevention and treatment of MS is physical activity and maintenance of proper relationship between lean and fat mass.
KeywordsMetabolic syndromeChronic kidney diseaseRenal transplantationHypertensionChildren
Definitions of metabolic syndrome issued by Adult Treatment Panel (ATP) and International Diabetes Federation (IDF)
International Diabetes Federation
The US National Cholesterol Education Program Adult Treatment Panel III
Central obesity (defined as waist circumference with ethnicity-specific values)
At least three of the following:
AND any two of the following:
•Triglycerides: > 150 mg/dl (1.7 mmol/l), or specific treatment for this lipid abnormality
•Central obesity: waist circumference ≥ 102 cm or 40 inches (male), ≥ 88 cm or 36 inches (female)
•HDL cholesterol: < 40 mg/dl (1.03 mmol/l) in males, < 50 mg/dl (1.29 mmol/l) in females, or specific treatment for this lipid abnormality
•Dyslipidemia: TG ≥ 1.7 mmol/l (150 mg/dl)
•Systolic BP > 130 or diastolic BP >85 mmHg, or treatment of previously diagnosed hypertension
•Dyslipidemia: HDL-C < 40 mg/dl (male), < 50 mg/dl (female)
•Fasting plasma glucose (FPG): >100 mg/dl (5.6 mmol/l), or previously diagnosed type 2 diabetes
•Blood pressure ≥ 130/85 mmHg
•Fasting plasma glucose ≥ 6.1 mmol/l (110 mg/dl)
If FPG is >5.6 mmol/l or 100 mg/dl, an oral glucose tolerance test is strongly recommended, but is not necessary to define presence of the syndrome
If BMI is >30 kg/m2, central obesity can be assumed and waist circumference does not need to be measure
Definition of metabolic syndrome in children – IDF criteria
Age group (years)
Glucose (mmol/l) or T2DM
6 to <10
Metabolic syndrome cannot be diagnosed, but further measurements should be made if there is a family history of metabolic syndrome, T2DM, dyslipidemia, cardiovascular disease, hypertension, and/or obesity
10 to <16
≥90th percentile or adult cut-off if lower
≥130 and/or diastolic ≥85 mmHg
(100 mg/dl) (If ≥5.6 mmol/l or known T2DM recommend an OGTT)
Use existing IDF criteria for adults:
Central obesity (defined as waist circumference ≥ 94 cm for Europid men and ≥ 80 cm for Europid women, with ethnicity specific values for other groups)
plus any two of the following four factors:
• raised triglycerides: ≥ 1.7 mmol/l
reduced HDL-cholesterol: <1.03 mmol/l (<40 mg/dl) in males and <1.29 mmol/l
(<50 mg/dl) in females, or specific treatment for these lipid abnormalities
• raised blood pressure: systolic BP ≥130 or diastolic BP ≥85 mmHg, or treatment of previously diagnosed hypertension
• impaired fasting glycemia (IFG): fasting plasma glucose (FPG) ≥5.6 mmol/l
(≥100 mg/dl), or previously diagnosed type 2 diabetes
MS is a challenge for pediatric nephrologists because of several reasons. Firstly, the main causes of chronic kidney disease (CKD) in adults, i.e., hypertensive and diabetic nephropathy, share the same pathophysiological abnormalities associated with visceral obesity and IR, both have origins in childhood and obesity-related nephropathy is now more often diagnosed in children [11–15]. Secondly, as the obesity epidemic has also reached children with CKD, MS may accelerate the progression of CKD. Thirdly, CV complications are the main cause of morbidity and mortality in children with CKD and MS may pose additional risk. Finally, although the renal transplantation (Rtx) reverses uremic abnormalities, it is associated with immunosuppressive drug-induced metabolic risk factors.
Pathogenesis of metabolic syndrome
The main abnormalities in MS include: IR, inflammation, endothelial dysfunction, oxidative stress, activation of the renin–angiotensin–aldosterone system (RAAS) and sympathetic nervous system. Caloric excess with dietary factors such as fructose, trans-unsaturated fatty acids, branched-chain amino acids, and reduced mitochondrial potential are implicated in the pathophysiology of MS. The dominant pathophysiological feature of MS is IR in the liver, adipose tissue, and skeletal muscles . Normally, insulin promotes glucose uptake into muscles, adipocytes, and hepatocytes and inhibits lipolysis in the adipose tissue. It also inhibits gluconeogenesis in the liver, where insulin-induced phosphorylation of a forkhead box protein O1 (FoxO1) prevents the expression of genes required for gluconeogenesis. Insulin also stimulates the activation of the transcription factor SREBP-1c, leading to transcription of genes required for triglycerides (TTG) and fatty acids (FA) production. Hepatic IR selectively removes the blockade of FoxO1 by insulin what increases gluconeogenesis and increases activation of SREBP-1c. The end result is increased synthesis of FA and TTG. Because of IR, insulin is unable to suppress lipolysis in the adipose tissue. It results in the release of more free FA into the plasma. The “portal theory” of MS is based on the phenomenon of venous drainage of the visceral adipose tissue directly into the portal system. The excess visceral fat causes the liver to be flushed with FA, which further enhances IR. The increased amount of free FA must be oxidized or stored and the excess TTG is secreted as very low density lipoprotein (VLDL). In muscles, IR reduces glucose uptake. IR is also modulated by hyperleptinemia or leptin resistance, adiposity-induced inflammation, and endothelial dysfunction .
Oxidative stress, probably as a secondary phenomenon, plays a significant role in the pathogenesis of childhood MS [17, 18]. High glucose and FA levels increase mitochondrial reactive oxygen species in endothelial cells, which may contribute to tissue dysfunction by dysregulation of signaling pathways or by oxidative damage to biological structures. Hyperleptinemia and angiotensin II activate the sympathetic nervous system. It decreases muscle blood flow, increases oxidative stress and insulin resistance. Specifically, angiotensin II inhibits insulin-mediated phosphatidylinositol-3-kinase. It leads to IR and lower glucose uptake, and to decreased endothelial nitric oxide production . Moreover, RAAS is involved in activation of both inflammation, IR, and oxidative stress. This phenomenon has been shown in spontaneously hypertensive rat (SHR), which is a model of genetic hypertension that allows a study of primary hypertension. It was shown that SHR fed a high-fructose diet developed MS, subclinical inflammation, and oxidative stress greater than in SHR fed a normal diet . Studies in children with PH have shown that subclinical inflammatory activity is associated with MS . Moreover, after 1 year of non-pharmacological and pharmacological treatment with the use of angiotensin convertase inhibitors (ACEi) or angiotensin receptor blockers (ARB), the prevalence of MS decreased by 50 %, immune activity normalized, and regression of target organ damage correlated with the decrease of WC . These findings indicate strong synergy between visceral obesity/altered body composition, IR, oxidative stress, and inflammatory activation .
CKD and uremia modulate the above-mentioned metabolic and immune mechanisms by influencing the secretion of appetite-regulating hormones such as leptin, ghrelin, obestatin, and adiponectin . CKD leads to changes in plasma levels of these hormones due to retention and altered metabolism. There are only a few pediatric studies analyzing relationships among appetite regulating hormones in children with CKD. In addition, they are biased by significant differences in body mass index (BMI) between healthy control children and CKD children. Nevertheless, serum levels of total ghrelin, an orexigenic and anti-inflammatory hormone, were significantly increased in children with CKD and on dialysis in comparison with healthy control children and children after Rtx . However, plasma levels of acylated ghrelin (the active form of the hormone) were the same as in the control group, whereas the deacylated form of ghrelin was increased . In contrast to acylated ghrelin, desacylated ghrelin is associated with malnutrition. Similarly, obestatin (an antiorexigenic hormone) levels were increased and leptin levels were the same as in the control group despite significantly lower BMI of children with CKD. It was shown that increased leptin levels were associated with fat mass, local and systemic inflammation, and MS in dialyzed patients [26–28]. Because obestatin is an antiorexigenic hormone and leptin is both an antiorexigenic and pro-inflammatory hormone, such alterations indicate that in CKD, metabolic equilibrium is moved towards anorexigenic, pro-inflammatory, and IR effects.
Recently, new hypotheses linking alterations in central nervous system regulation of cardiovascular system and immuno-metabolic abnormalities in the form of MS have been proposed [29, 30]. In short, there is evidence that increased sympathetic activity from cardiovascular networks in the brain, as is present during chronic stress or in depression, is associated with the development of obesity, and visceral obesity in particular, and immune activation and cytokines secretion may have direct effect on central sympathetic activation.
The pathological basis of cardiovascular complications in chronic kidney disease
CVD is the main cause of death in CKD in both adults and children . Because CKD in adults is caused by hypertensive and diabetic nephropathy, CVD is the main clinical problem already before late stages of CKD . On the contrary, in children with CKD, the clinically evident CVD develops at the late stages of disease, usually in dialyzed patients . The pathogenesis of CVD differs in relation to the stage of CKD. In advanced CKD, CVD is caused by three overlapping processes: atherosclerosis, uremic arteriosclerosis, and uremic cardiomyopathy. In 1974, Lindner et al. reported that hemodialyzed adults suffered from accelerated atherosclerosis . However, although both atherosclerosis and uremic arteriosclerosis share the same risk factors as hypertension, dyslipidemia, hyperhomocysteinemia, and low-level inflammation, etc., the basic mechanisms are different. Atherosclerotic arterial injury starts in the endothelium and the main risk factor is dyslipidemia, which leads to infiltration of arterial wall by lipids, inflammatory reaction, and development of atherosclerotic plaque. Hypercholesterolemia, and especially atherogenic dyslipidemia with elevated low density lipoprotein (LDL) cholesterol, hypertriglyceridemia, and low-high density lipoprotein (HDL) cholesterol, is the most important factor and even in the absence of other factors leads to atherosclerosis. The other risk factors such as hypertension, IR, smoking, etc., which cause mechanical damage to the endothelial layer, facilitate lipids infiltration and accelerate the process . Atherosclerosis is focal and refers to large- and medium-sized arteries. The heart is damaged by repeated episodes of ischemia.
The different pathological basis of CV complications caused by uremia and of those caused by metabolic abnormalities typical of MS leading to atherosclerosis explain the discrepant results of treatment with anti-atherosclerotic drugs in relation to stage of CKD.
The prevalence of metabolic syndrome among children and adolescents.
Using the IDF definition, US National Health and Nutrition Survey data from 1999–2004 showed that among adolescents aged 12–17 years, the prevalence of MS was 4.5 %. It increased from 1.2 % in 12 years old to 7.1 % in 16–17 years old . In the European Youth Heart Study, the prevalence of MS defined according to the IDF was 0.2 % in 10-year-old and 1.4 % in 14-year-old children . Similar data on the prevalence of MS among 10-year-old children were reported in Greece . In Poland, the prevalence of MS among adolescents from urban population ranged from 1.4 to 2.2 %, but among children with PH was ten times higher than in the general population and ranged from 15 to 20 % [6, 8].
The prevalence of metabolic abnormalities and metabolic syndrome in CKD
Metabolic abnormalities, changes in body composition with growth failure, the decrease of LBM, and the increase of visceral fat correlate with decreasing GFR. However, there are relatively scanty data on the prevalence of MS in children with CKD. Children with CKD are shorter and weigh relatively more than healthy children, which is evident from stage 3 CKD [47–49]. This effect is now modulated by environmental and lifestyle changes and it was reported that children with CKD are more overweight nowadays than two decades ago [50, 51]. Dyslipidemia and glucose intolerance are typical metabolic abnormalities of CKD. Reports from the CKID Study indicate that the most typical abnormality in children with CKD stage 2–4 is hypertriglyceridemia . It was estimated that every 10 ml/min/1.73 m2 decrease of GFR was associated with an increase of serum concentration of TTG by 8 %, an increase of LDL cholesterol concentration by 2 %, and a decrease of HDL cholesterol concentration by 3 %. Proteinuria was associated with these abnormalities and they occurred in children with nephrotic proteinuria twice more often compared to non-proteinuric children.
Another analysis from the CKID Study revealed that 46 % of children with CKD stage 2–4 had hypertension, 44 % had dyslipidemia, 15 % were obese, and 21 % presented with disturbed glucose metabolism. At least three aforementioned cardiovascular risk factors were found in 13 % of patients . Therefore, according to some definitions, the prevalence of MS in this cohort may be estimated as about 13 % what is greater than in general pediatric population. However, this is still much lower than in adults with CKD. Kwan et al. found that in adults with mean GFR 46 ml/min/1.73 m2 the prevalence of MS ranged from 9 to 58 % across BMI values from below 20 to above 35. In contrast, in adults with mean GFR 87 ml/min/1.73 m2 the prevalence of MS was 1 to 35 % across the same ranges of BMI . Wu et al. found MS in 50.5 % of dialyzed adults when the ATP III definition was used, and in 30.8 % when the IDF definition was used . As in the general population, MS significantly increases CV risk in adults with CKD and even in dialyzed patients. Recent study indicates that abdominal obesity as measured using WC was the most significant predictor of CV events in hemodialyzed adults . It must be pointed out that the relationship between obesity, BMI, and CV risk in dialyzed patients is curvilinear. The CV morbidity and mortality is increased among dialyzed patients with low and even normal BMI in comparison with patients who had elevated BMI. However, detailed analysis revealed that the protective effect of high BMI was limited to patients with normal or high muscle mass .
Metabolic syndrome in children after renal transplantation
Normalization of metabolic abnormalities caused by uremia and even some reversal of uremic arterial and cardiac damage after Rtx depends on GFR of transplanted kidney [57, 58]. However, the immunosuppressive therapy to prevent organ rejection also causes significant metabolic abnormalities such as atherosclerotic dyslipidemia, IR, and the risk of new-onset diabetes after transplantation (NODAT). These abnormalities, typical for MS, are accompanied by visceral obesity and the decrease of LBM. Therefore, the resultant depends on GFR and the side effects of immunosuppressive drugs.
The average prevalence of MS in adults after Rtx is approximately 60–70 %. Obesity is the main risk factor for the development of MS after Rtx and MS increases CV risk [59, 60]. The averaged results from pediatric studies indicate that the prevalence of MS significantly increases after Rtx and is higher compared to the general population and in dialyzed children. Wilson et al. reported that the prevalence of MS in children 1 year after Rtx was 37.6 % and two-thirds of them developed MS de novo . Höcker et al. found that the prevalence of MS after Rtx depended on a time from Rtx and the use of corticosteroids (CS) and ranged from 40 % in the first months after Rtx to 20 % after 2 years .
Children after Rtx who had MS also had greater left ventricular mass and left ventricular hypertrophy developed in 55 % of them compared with 32 % without MS . The eccentric left ventricular hypertrophy, typical for obesity and MS, was found in 34 % of children with MS, compared with 15 % in children without MS.
CS play a crucial role in the pathogenesis of MS after Rtx. Höcker et al. showed that in patients in whom corticosteroids were withdrawn, the prevalence of MS fell to 5 % after 1 year . Similarly, an exposure to MS factors significantly decreased in this group in comparison to children in whom treatment with CS was continued. The use of greater doses of CS is a derivative of HLA matching and rejection episodes. It was found that MS prevalence was three times lower among recipients of living donor grafts than among recipients of cadaver donor grafts .
The most severe metabolic complication of CS after Rtx is NODAT. It seems that the first description of NODAT after Rtx was given by Starzl in 1964 . Although azathioprine usage is also associated with a pancreatic injury, it seems that the prevalence of NODAT increased significantly with the introduction of calcineurin inhibitors (CNI) in mid-eighties of XX century . Cyclosporin (CSA) and especially tacrolimus (TAC) have the potential to directly damage pancreatic β cells . A comparison of registry data from the last three decades suggests that the prevalence of NODAT increased from below 10 % in the 1980s to 20-30 % in the last decade . The US Renal Data System analysis showed that the prevalence of NODAT in transplanted children increased from 2-3 % in the late-1980s to 7.5 % recently . The NAPRTSC report showed an increased prevalence of NODAT in children after Rtx, however the change presented only statistical tendency . Nevertheless, both reports indicate the trend for an increased prevalence of NODAT in transplanted children in the last decades.
The pathogenesis of NODAT is multifactorial and all risk factors for diabetes including CS and CNI play a role. TAC is a stronger risk factor for NODAT than CSA . However, the risk factors for NODAT operate already during dialysis period, and include peritoneal dialysis and obesity . The other risk factor is hyperglycemia during the postoperative period . Peritoneal dialysis, overweight, the usage of CNI and posttransplant hyperglycemia seem all to be risk factors of NODAT.
Metabolic syndrome as a risk factor of CKD in children
Because the number of nephrons does not increase with increasing body fat, obesity must cause the increase of single-nephron GFR, and the absolute values of GFR should increase as a consequence of increased GFR and filtration fraction. Chagnac et al. reported that GFR was 51 % greater in obese non-diabetic adults than in non-obese, healthy controls. It was associated by proportionally lower (on average 31 %) increase in renal plasma flow and was accompanied by slightly increased but still in normal range mean arterial pressure. This resulted in a filtration fraction of 17 % in obese in comparison with 15 % in non-obese subjects . Chagnac et al.  found that ultrafiltration coefficient did not change. The other finding was that the obese subjects were exposed to the greater glucose and insulin concentrations expressed as the areas under the curves after oral glucose load. The changes in glomerular hemodynamics have been confirmed by clinical observations. MS and its main criteria associate with CKD and are predictors for incident of CKD in adults. The best confirmation of this pathogenical link is hypertensive and diabetic nephropathy as the main causes of CKD [76, 77]. Each criterion of MS is associated with the risk of CKD, however, hypertension has the greatest impact . Most of the studies evaluating the relationship between anthropometrical parameters and the risk of CKD analyzed only BMI. It was found that BMI together with other factors such as diabetes, smoking, and low GFR was associated with the risk of CKD [78, 79]. However, when other parameters of adiposity such as WC were analyzed, it was shown that the renal risk associated with MS was not associated with increased BMI but with visceral obesity and the probability of incident CKD increased from the lowest to highest WC quartile . Similarly, in the Diabetes Control and Complications Trial, it was found that every 10-cm increase in WC was associated with a 35 % increased risk of incident albuminuria in adults with type 1 diabetes .
The time delay between exposure to metabolic abnormalities and kidney injury explains that the first abnormalities are only surrogate markers of progressive CKD. It was found that in obese children and children with non-alcoholic fatty liver disease, exposure to MS criteria impaired glucose tolerance and IR correlated with microalbuminuria and hyperfiltration [82–84]. Kolouridis et al. found that the exposure to the MS criteria correlated positively with GFR. However, GFR decreased when children were exposed to more than four MS criteria . Prospective study of adolescents and young adults (mean age 18 years) found that being overweight, hypertension, and low-HDL cholesterol concentration increased the probability of hyperfiltration 6.6-fold. Moreover, high metabolic risk correlated with hyperfiltration and preceded development of overt nephropathy . The general conclusion is that the first abnormality observed in children with MS is hyperfiltration, and albuminuria develops at later stages followed by the decrease of GFR.
Although the pathogenesis of progressive renal injury related to MS is multifactorial it is at least partly explained by phenomena observed in obesity-related glomerulopathy (ORG). The first report on the relationship between obesity and kidney injury came from Preble who reported in 1923 that obesity was associated with proteinuria . However, Weisinger et al. first described both clinical course and biopsy findings in kidneys of four obese adults who presented with MS and nephrotic proteinuria . Proteinuria decreased with weight loss but in patients who re-gained weight proteinuria reappeared. Cardiac catheterization found an increased right atrial pressure. The renal biopsies revealed segmental sclerosis.
Historically, the pathogenesis of renal injury in ORG and ORG-FSGS was explained as a consequence of increased venous pressure documented by increased right atrial pressure and modest hypoxemia caused by accompanying sleep apnea . However, the functional studies that documented hyperfiltration with increased intraglomerular pressure and albuminuria preceding overt proteinuria fits well with the hyperfiltration theory. Moreover, an elevated blood pressure, arteriolopathy, and exposure to MS are similar to the pathogenesis of hypertensive nephropathy and nephropathy in type 2 diabetes. Thus, MS will cause an additional burden especially in patients with CKD suffering already from low nephron number due to disease or prematurity.
Treatment of metabolic syndrome and metabolic abnormalities in children with CKD
Treatment of MS, both in the general population and in children with CKD, is aimed at reversal of IR and normalization of metabolic and hemodynamic abnormalities. It may be achieved by reduction of mitochondrial load by a decrease of substrate availability, a decrease of FA flux to the liver, and an increase in the number of mitochondria . The first aim may be achieved by caloric restriction with dietary modification leading to the decrease of the glycemic index. An increased amount of fiber in the food may decrease FA flux. Physical exercise and an increase in LBM lead to the formation of new mitochondria in the liver and in skeletal muscles. Dietary modifications with significant limitations of sugar, and especially of fructose, in the diet, has been found effective in terms of both the normalization of metabolic abnormalities, decrease or stabilization of cIMT, and improvement of endothelial function assessed by flow-mediated dilation (FMD) in children with MS [93, 94]. However, when dietary modifications and physical exercise were combined, FMD of the brachial artery was much more improved. The important observation is that after stopping of an exercise program, FMD decreased to basal values . In adolescents with PH and MS, 1 year of non-pharmacological treatment based on physical activity alone or combined with blockade of RAAS resulted in a decrease of the prevalence of MS by 50 % and the main predictor of improvement was the decrease of WC .
Non-pharmacological treatment strategies
There are only a few reports on the effectiveness of the non-pharmacological treatment of MS in children with CKD or after Rtx. As in other chronic diseases, children with CKD are less physically active and have lower cardiorespiratory fitness assessed as maximal oxygen uptake in comparison with healthy children . The analysis of children and adolescents with CKD, on dialysis and after Rtx, has shown that physical activity was uniformly low in all three groups. In addition, females were less active than males and older patients, aged 18–20 years, had significantly lower physical activity in comparison with younger patients. Moreover, the results of a standardized 6-min walk distance test were below 2 and 4 standard deviations from the mean of normal values in boys and girls, respectively. The level of physical activity was associated negatively not only with BMI but also positively with maternal education level . In adults with pre-dialysis CKD and on dialysis, effective physical activity treatment caused an increase in cardiorespiratory fitness, a decrease of WC, and an increase in LBM . Such changes associate with an improved biochemical profile . Similarly, in children with CKD, on dialysis and after Rtx, implementation of programs of physical activity resulted in cardiorespiratory fitness improvement, a decrease of blood pressure, and left ventricular mass . However, children after Rtx had to be physically active for at least 3–5 h/week to attain cardiorespiratory fitness of healthy children who led a sedentary life-style (physical activity below 3 h/week). Although there are no recommendations prepared especially for children with CKD, general pediatric recommendations advise that daily physical activity should be at least 60–90 min of accepted anaerobic exercise . One of the limiting factors of the anabolic effect of exercise and increase of lean body mass in CKD patients is acidosis . The other limiting factor of life-style interventions in children with CKD and after Rtx is non-compliance. It was reported that half of all children after Rtx declined to participate in physical activity program and none of the patients complied with dietary limitations . Nevertheless, it must be stressed that the lifestyle interventions in the treatment of MS, although difficult to implement, have been shown to be more efficient than pharmacological treatment .
Pharmacological treatment strategies
Potentially available pharmacological interventions in MS rely on the treatment of dyslipidemia, IR, and arterial hypertension. Although elevated LDL cholesterol is not a criterion of MS, it is commonly observed in children with MS and CKD or after Rtx.
Treatment of dyslipidemia
Statins lower both total cholesterol, LDL cholesterol, and, to a lesser extent, TTG concentrations. In adults with CKD, statins are effective both in lowering LDL cholesterol and decreasing the incidence of CV events. However, this beneficial effect was observed only in patients with CKD stage 2–4. In dialyzed patients, statins led to a decrease of LDL cholesterol concentrations but it did not affect CV morbidity and mortality except of patients with diabetes [104, 105]. In the SHARP study, simvastatin with ezetimibe reduced CV events and CV mortality but only those caused by atherosclerosis and not by uremic arteriopathy . Similarly, statins used after Rtx decrease the risk associated with atherosclerosis but the main risk is still related to the low GFR and uremic arteriopathy . It is not unexpected in light of different pathological basis of CVD in CKD and on dialysis, as discussed above. Statins used in children with familial hypercholesterolemia reduced both total and LDL cholesterol and cIMT . Simvastatin used in a non-homogenous group of children with CKD and with modestly reduced GFR led to a reduction of total (by 23 %), LDL cholesterol (by 34 %), and TTG (by 21 %) concentrations . However, in a small cross-over trial of atorvastatin in eight children with CKD and GFR below 60 ml/min/1.73 m2, despite a significant lowering of LDL cholesterol, there was no change in flow-mediated dilation of brachial artery .
The drugs of choice in the treatment of hypertriglyceridemia are fibrates or niacin. As in the case of statins, fibrates used in adults with mild to moderate CKD reduced CV events and, similarly to statins, were renoprotective. However, fibrates also did not reduce CV events in patients on dialysis . There are only a few reports on use of fibrates in children. Nevertheless, a treatment algorithm for the use of fibrates in children was proposed . According to it, in any case, except of TTG levels above 900 mg/dl, the first step should be life-style and dietary modifications with a significant decrease of sugar consumption.
Recommendations on treatment of dyslipidemia in children from high-risk groups
The American Heart Association (AHA) issued recommendations on the treatment of children from high-risk groups including CKD, children with dyslipidemia, and children with MS [17, 102, 113]. The AHA Expert Panel recommended to stratify cardiovascular risk in relation to the family history of CVD and presence of comorbidities such as obesity, hyperglycemia, hypertension, dyslipidemia, and low physical activity. In the case of presence of the above-mentioned comorbidities/risk factors, the AHA recommends treatment (both non-pharmacological and pharmacological) to achieve LDL cholesterol below 100 mg/dl, normoglycemia, normal weight, and normal blood pressure. In patients without additional risk factors, LDL cholesterol should be lowered below 130 mg/dl. The AHA recommends using statins if LDL cholesterol is above 130 mg/dl, despite dietary intervention. Simvastatin and atorvastatin are metabolized by cytochrome P450 3A4 and pravastatin and fluvastatin can be metabolized also by alternative metabolic routes. Involvement of cytochrome P450 in statin metabolism interacts with CNI metabolism, especially with CSA. It was found that in adults after Rtx who were treated with atorvastatin, plasma concentrations of atorvastatin increased sixfold and the CSA area under curve decreased by 9.5 % . According to the 2009 AHA statement on MS in children, fibrates or niacin should be used if triglyceride levels are above 1,000 mg/dl despite dietary and life-style modifications . Because of the possibility of adverse reactions of both statins and fibrates, especially of rhabdomyolysis, their use should be carefully considered.
Despite the existing recommendations, the use of pharmaceutical products to treat dyslipidemia in children with CKD and MS is controversial. Due to the different etiology of CKD and pathogenesis of CVD in children with CKD, expert statements do not recommend wide use of statins in children with CKD . Moreover, the recent meta-analyses showed that statins used longer than 1 year increase by 9 % the risk of incident diabetes and intensive treatment increases this risk by additional 12 % [116, 117]. In children after Rtx and with MS, typical atherogenic dyslipidemia may coexist with MS. Thus, life-style interventions may be successfully combined with statins and/or fibrates. The best option is use of the lowest possible dose of CS or CS-free immunosuppressive protocol, if possible.
Anti-obesity drugs may be the option in children with severe obesity. However, it must be pointed out that only orlistat is licensed for use in the treatment of obese adolescents. Moreover, orlistat has limited efficiency and produces significant side effects . Sibutramine, an anti-appetite drug, has been withdrawn because of severe cardiovascular toxicity.
Theoretically, insulin sensitizers seem to be the best pharmacological option in MS . In contrast to adult studies, there are only a few reports on the use of metformin in children with CKD. Metformin is used in children with MS and glucose levels above 126 mg/dl when non-pharmacological treatment is ineffective . Because of a relatively safe profile when GFR is above 60 ml/min/1.73 m2, it may be of help in treatment of children with MS and risk of incident CKD. However, use of metformin in CKD is limited by decreased elimination. In patients with GFR below 40 ml/min/1.73 m2, there is more than a 10 % risk of lactic acidosis. Thiazolidinediones, the other insulin sensitizers, may cause hypoglycemia . Nevertheless, the use of thiazolidinediones in diabetic adults on dialysis was associated with significantly lower mortality in patients who were insulin independent but not in those who required insulin treatment .
Treatment of elevated blood pressure in children with MS and with CKD or after Rtx should take into account the pathogenetic mechanisms of hypertension, metabolic abnormalities, and potential renoprotective effects. It has been shown both in experimental studies and in clinical trials that blockade of RAAS leads to significant improvement of insulin sensitivity and normalization of metabolic abnormalities . In addition, it was shown that chronic use of ACEi was associated with a lower rate of development of type 2 diabetes in middle age and older adults with arterial hypertension . Thus, the drugs of choice in the treatment of hypertension in children with MS are ACEi or angiotensin 2 receptor type 1 blockers (ARB) . In children with CKD, RAAS inhibitors have also renoprotective effect . However, efficacy of ACEi/ARBs in monotherapy decreases with decrease of GFR and with sodium retention. If monotherapy with ACEi/ARBs is not sufficient, the choice of second and third drug should also take into account metabolic effects.
Dihydropyridine calcium channel blockers have lower renoprotective potential but are devoid of adverse metabolic effects and may be used together with ACEi or ARBs. Similarly, alpha-adrenolytics also have beneficial metabolic profiles. In contrast, beta-adrenolytics aggravate metabolic abnormalities including IR . However, so known vasodilating beta-adrenolytics such as nebivolol have significantly better metabolic profiles in comparison with older beta blockers such as metoprolol . Nevertheless, in children who have volume-dependent hypertension, diuretics may be the last and best option.
In conclusion, from a practical point of view, the best and safest way of prophylaxis and therapy of MS in children with CKD, on dialysis and after Rtx, is physical activity and dietary modifications. Life-style modifications, when successfully implemented, have greater effects than pharmacological therapy. ACEi or ARBs lower blood pressure, slow progression of CKD, and seem to improve metabolic abnormalities. Pharmacological intervention for dyslipidemia and impaired glucose tolerance/IR should be limited to cases when non-pharmacological treatment is not effective. In children after Rtx minimal dose of CS or CS free protocol is the best option both in prevention and treatment of MS.
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.